United StatesNovartis reported a 3% increase in net sales to $14.4 billion, exceeding expectations, while core operating profit remained stable at $5.94 billion. The growth was driven by strong performance in cancer and multiple sclerosis treatments, which helped counterbalance the significant decline in sales of the heart failure drug Entresto.
Bias read (Center): The article presents factual financial results without overt ideological framing. It highlights both positive and negative aspects of Novartis' performance, focusing on market dynamics rather than political implications. There is no clear leaning toward either progressive or conservative viewpoints.
